Pasar al contenido principal

DISECCION DEL PAPEL DEL COMPLEJO SWI/SNF EN EL DESARROLLO TUMORAL

PID2021-126111OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE GRANADA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

High-fidelity Cas9-mediated targeting of KRAS driver mutations restrains lung cancer in preclinical models

  • Alvarez-Perez, Juan Carlos
  • Sanjuan-Hidalgo, Juan
  • Arenas, Alberto M.
  • Hernandez-Navas, Ivan
  • Benitez-Cantos, Maria S.
  • Andrades, Alvaro
  • Calabuig-Farinas, Silvia
  • Paz-Ares, Luis
  • Ferrer, Irene
  • Medina, Pedro P.
  • Jantus-Lewintre, Eloisa|||0000-0001-7395-4380
[EN] Missense mutations in the 12th codon of KRAS are key drivers of lung cancer, with glycine-to-cysteine (G12C) and glycine-to-aspartic acid (G12D) substitutions being among the most prevalent. These mutations are strongly associated with poor survival outcomes. Given the critical role of KRAS in lung cancer and other cancers, it remains as a major target for the development of new and complementary treatments. We have developed a CRISPR-High Fidelity (HiFi)-Cas9-based therapy strategy that can effectively and specifically target KRASG12C and KRASG12D mutants, avoiding KRASWT off-targeting and affecting KRAS downstream pathways, thereby significantly reducing tumorgenicity. The delivery of HiFiCas9 components via ribonucleoprotein particles (RNPs) and adenovirus (AdV) effectively abrogates cell viability in KRAS-mutant Non-Small Cell Lung Cancer (NSCLC) preclinical models, including 2D and 3D cell cultures, cell-derived xenografts (CDX), and patient-derived xenograft organoids (PDXO). Our in vitro studies demonstrate that HiFiCas9-based therapy achieves superior KRAS inhibition compared to Sotorasib and effectively circumvents certain resistance mechanisms associated with Sotorasib treatment. Moreover, in vivo delivery using adenoviral particles significantly suppresses tumor growth in preclinical NSCLC models. Collectively, our findings establish HiFiCas9 as an effective therapeutic strategy with promising clinical applications, especially if in vivo delivery methods are further optimized., P.P.M.'s laboratory is supported by the grants PID2021-126111OB-I00 and PID2024-159252OB-I00, funded by the MCIN/AEI/10.13039/501100011033 and by ERDF ("A way to make Europe"), the Spanish Association Against Cancer (LAB-AECC-2018), the Junta de Andalucia (PI-0203-2022 and PI-0228-2024), and the University of Granada (B-CTS-480-UGR20, C-EXP-051-UGR23, C-CTS-149-UGR23). J.S.-H. is supported by a grant from the Scientific Foundation of the Spanish Association Against Cancer in Granada (#PRDGR21428SANJ). J.C.A.-P. was supported by an MSCA-IF-EF-RI 837897 fellowship (Horizon 2020 Framework Programme). A.M.A. was supported by an FPU17/01258 fellowship. A.A. was supported by an FPU17/00067 fellowship (Spanish Ministry of Science, Innovation, and Universities) and by the Programa de Contratos Puente (Plan Propio 2022) of the University of Granada. M.S.B.-C. was supported by an FPU19/00576 fellowship (Spanish Ministry of Science, Innovation, and Universities). E.J.-L.'s laboratory is funded by the Spanish Association Against Cancer (PROYE18012ROSE), the Instituto de Salud Carlos III (PI22/01221), and CIBERONC (CB16/12/00350). We would like to thank Ms. Rosario Martin from Ecija for her donation to promote research into lung cancer. The authors acknowledge the support of the ROLUCAN Association (Rota Lucha Contra el Cancer) for facilitating this research, and the Ph.D program of Biochemistry and Molecular Biology of the University of Granada.